Abstract: In brief: The ability of CD8⁺ T cells to recognize and kill cancer cells is a key component of various immunotherapies. Despite progress toward characterizing tumor reactive T cell repertoires, it is challenging to identify the target antigens required for recognition. Accordingly, the authors have developed a chimeric receptor referred to as the signaling and antigen-presenting bifunctional receptor (SABR) that allows for the high-throughput screening and identification of T cell receptor antigens through intracellular signaling pathways.

Originally published at chemistry.nd.edu.